BBV prevalence and risk factors among IDUs
| All (314) | AA (223) | IA (34) | SEA (22) | Other (35) | p Value | |
|---|---|---|---|---|---|---|
| Where the denominator is less than the total number of individuals in each group, individuals omitted have not been tested. | ||||||
| AA, Anglo-Australian; IA, Indigenous Australian; SEA, South East Asian; Other = predominantly Middle Eastern and European. | ||||||
| HCV, hepatitis C; HBV, hepatitis B; anti-HBs = HBV surface antibody, anti-HBc = HBV core antibody, sAg, surface antigen; HAV, hepatitis A; P, positive; IE, injecting equipment. | ||||||
| *Lack of pretest awareness of HCV infection is presented for those who were HCV antibody positive on testing. | ||||||
| Mean age (years) | 26 | 26 | 28 | 22 | 24 | 0.001 |
| HCV antibody | 232/314 (74%) | 163/223 (73%) | 32/34 (94%) | 12/22 (55%) | 25/35 (71%) | 0.009 |
| Anti-HBc | 102/311 (33%) | 60/221 (27%) | 15/34 (44%) | 11/22 (50%) | 16/34 (47%) | 0.01 |
| HBVs Ag | 9/311 (3%) | 1/198 (1%) | 2/30 (7%) | 3/22 (14%) | 3/34 (9%) | <0.001 |
| Anti-HBs | 163/288 (57%) | 102/199 (51%) | 15/34 (44%) | 11/22 (50%) | 24/35 (69%) | 0.19 |
| HAV antibody | 87/307 (28.3%) | 44/217 (20%) | 20/33 (61%) | 14/22 (64%) | 9/35 (26%) | <0.001 |
| HIV antibody | 3/309 (1%) | 0/219 | 0/34 | 3/21 (14%) | 0/35 | <0.001 |
| Median duration of heroin use (years) | 4 | 4 | 5 | 4 | 3 | 0.14 |
| Shared drug IE in past 6 months | 158/286 (55%) | 100/204 (49%) | 28/32 (88%) | 10/19 (53%) | 20/31 (65%) | <0.001 |
| Ever shared drug IE | 235/284 (83%) | 178/202 (88%) | 31/32 (97%) | 13/19 (68%) | 26/31 (84%) | 0.03 |
| Never tested for BBVs | 35/307 (11%) | 18/216 (8%) | 5/34 (15%) | 7/20 (35%) | 20/35 (57%) | <0.001 |
| Pretest unaware of HCV infection* | 84/232 (36%) | 51/163 (31%) | 17/32 (53%) | 7/12 (58%) | 9/25 (36%) | 0.04 |
| HBV susceptible | 111/288 (39%) | 89/199 (45%) | 9/32 (28%) | 3/22 (14%) | 10/34 (30%) | 0.009 |
| HCV p<25 year old | 112/171 (66%) | <0.001 | ||||
| HCV p⩾25 year old | 120/143 (84%) | |||||
| HCV P in IDUs injecting <3 years | 50/98 (51%) | <0.001 | ||||
| HCV P in IDUs injecting ⩾3 years | 182/216 (84%) | |||||
| History of blood transfusion | 18/314 (6%) | |||||
| Body piercing | 201/300 (67%) | |||||
| Tattoos | 188/299 (63%) | |||||